Analysts Set Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Target Price at $15.33

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) has earned an average recommendation of “Buy” from the five ratings firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $15.3333.

Several research analysts have recently commented on RADX shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Radiopharm Theranostics in a research report on Thursday, January 22nd. Wall Street Zen cut Radiopharm Theranostics to a “strong sell” rating in a research note on Friday, January 23rd. Finally, B. Riley Financial reiterated a “buy” rating and set a $16.00 target price (up previously from $13.00) on shares of Radiopharm Theranostics in a research note on Tuesday, December 16th.

Radiopharm Theranostics Trading Down 0.8%

NASDAQ:RADX opened at $4.98 on Wednesday. Radiopharm Theranostics has a one year low of $3.50 and a one year high of $16.25. The stock has a 50-day simple moving average of $5.22 and a 200 day simple moving average of $5.39.

Institutional Investors Weigh In On Radiopharm Theranostics

Several institutional investors and hedge funds have recently bought and sold shares of the business. PNC Financial Services Group Inc. grew its holdings in shares of Radiopharm Theranostics by 100.0% during the third quarter. PNC Financial Services Group Inc. now owns 16,000 shares of the company’s stock valued at $88,000 after purchasing an additional 8,000 shares during the last quarter. Jane Street Group LLC acquired a new position in Radiopharm Theranostics during the 4th quarter valued at approximately $76,000. Finally, Marex Group plc bought a new position in Radiopharm Theranostics during the 4th quarter worth $54,000.

Radiopharm Theranostics Company Profile

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.